Alpha Tau Medical (DRTS) Research & Development (2021 - 2026)
Alpha Tau Medical (DRTS) posted Research & Development of $11.0 million for Q1 2026, up 14.61% sequentially from $9.6 million in Q4 2025, and up 53.07% YoY from $7.2 million in Q1 2025.
Alpha Tau Medical (DRTS) Research & Development (2021 - 2026) Analysis & Trends
Alpha Tau Medical has reported Research & Development for 6 years, with the latest figure at $11.0 million in Q1 2026.
- Quarterly Research & Development rose 53.07% year-over-year to $11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.9 million (up 29.3% YoY) and the FY2025 annual result came in at $32.1 million, up 18.67% from the prior year.
- Research & Development advanced to $11.0 million in Q1 2026 per DRTS's latest filing, from $9.6 million in the prior quarter.
- Over five years, Research & Development peaked at $11.0 million in Q1 2026 and troughed at $4.8 million in Q3 2022.
- A 5-year average of $6.9 million and a median of $6.7 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2024: Research & Development surged 139.15% in 2022, then slipped 7.49% in 2024.
- Over 5 years, Research & Development stood at $5.4 million in 2022, then surged by 39.22% to $7.5 million in 2023, then grew by 0.57% to $7.5 million in 2024, then advanced by 27.12% to $9.6 million in 2025, then rose by 14.61% to $11.0 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $11.0 million, $9.6 million, and $8.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Alpha Tau Medical | 1.32 Bn | 1.32 Bn | - | 9.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.91 Mn |
| Mar 31, 2026 | 10.98 Mn |
| Dec 31, 2025 | 9.58 Mn |
| Sep 30, 2025 | 8.31 Mn |
| Jun 30, 2025 | 7.01 Mn |
| Mar 31, 2025 | 7.17 Mn |
| Dec 31, 2024 | 7.53 Mn |
| Sep 30, 2024 | 6.17 Mn |
| Jun 30, 2024 | 6.87 Mn |
| Mar 31, 2024 | 6.45 Mn |
| Dec 31, 2023 | 7.49 Mn |
| Sep 30, 2023 | 6.67 Mn |
| Jun 30, 2023 | 5.96 Mn |
| Mar 31, 2023 | 6.31 Mn |
| Dec 31, 2022 | 5.38 Mn |
| Sep 30, 2022 | 4.83 Mn |
| Jun 30, 2022 | 5.45 Mn |
| Mar 31, 2022 | 5.24 Mn |
| Dec 31, 2021 | 3.23 Mn |
| Sep 30, 2021 | 3.03 Mn |